1. A method of reducing the level of triglycerides in an individual with an initial fasting triglyceride level of from 500 mg / dl to about 1500 mg / dl, comprising orally administering to an individual about 4 g per day of a pharmaceutical composition containing at least about 80%, by weight of all fatty acids present acids, ethylacosapentaenoate. 2. A method for reducing an individual’s triglyceride level with an initial fasting triglyceride level of from 500 mg / dl to about 1500 mg / dl, comprising orally administering 4 capsules per day to an individual, where each capsule contains about 1 g of fatty acids, where at least about 80% of the fatty acids are acids are ethyleicosapentaenoate. 3. The method of claim 1 or. 2, where the individual's level of triglycerides decreases compared with placebo. 4. A method according to claim 1 or 2, wherein the level of triglycerides in an individual is reduced compared to the initial level. The method according to claim 4, wherein the individual's level of triglycerides is reduced by at least about 25% compared with the initial level. A method according to claim 1 or 2, wherein the individual has a lower level of triglycerides compared to another individual having an initial fasting triglyceride level of from 500 mg / dl to about 1500 mg / dl, which did not take the pharmaceutical composition. The method of claim 6, wherein the individual has a triglyceride level reduction of at least about 20% compared to another individual. The method according to claim 1 or 2, where the individual decreases the level of apolipoprotein B.9. The method of claim 1 or 2, wherein the individual does not substantially increase the level of LDL-C.10. The method of claim 9, wherein the individual decreases LDL-C.11. The method of claim 4, wherein the level of LDL-C is increased by no more than 5%.1. Способ снижения уровня триглицеридов у индивида с исходным уровнем триглицеридов натощак от 500 мг/дл до приблизительно 1500 мг/дл, включающий перора
